BACKGROUND: Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity. Tac pharmacokinetics varies between individuals and thus complicates its use in preventing rejection after kidney transplantation. This variability might be caused by genetic polymorphisms in metabolizing enzymes.
CONCLUSIONS:
The CYP3A4 rs35599367CϾT polymorphism is associated with a significantly altered Tac metabolism and therefore increases the risk of supratherapeutic Tac concentrations early after transplantation. Analysis of this CYP3A4*22 SNP may help in identifying patients at risk of Tac overexposure.
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CYP3A4 is the most abundant cytochrome P450 enzyme in the human liver and is responsible for the metabolism of 45%-60% of prescribed drugs (1 ) . CYP3A4 activity varies widely, with 10-to 100-fold variation between individuals (2) (3) (4) (5) . A recent study identified a functional single-nucleotide polymorphism (SNP) 5 in intron 6 (CYP3A4*22) that was associated with decreased CYP3A4 production and activity and that was correlated with the statin dose requirement for lipid concentration control (6 ) .
The immunosuppressive drug tacrolimus (Tac) is extensively metabolized by CYP3A4 and CYP3A5 (7) (8) (9) . The *3 allele of the CYP3A5 6 (cytochrome P450, family 3, subfamily A, polypeptide 5) gene, which codes for the absence of CYP3A5 (10 ) , was previously associated with the Tac predose concentration (C 0 ) and Tac dose requirements. The CYP3A5 genotype explains a major portion of the interindividual variation in Tac pharmacokinetics: carriers of 2 CYP3A5*3 nonfunctional alleles require substantially less Tac (about 50% less) to reach an identical C 0 concentration (11, 12 ) than kidney, liver, lung, and heart transplant recipients carrying a CYP3A5*1 active allele. The clinical benefit of CYP3A5-based Tac dosing remains debatable, however (13, 14 ) . The drug transporter encoded by the ABCB1 [ATP-binding cassette, sub-family B (MDR/ TAP), member 1] gene is also involved in Tac disposition. Genetic variants have been associated with Tac drug disposition, although contradictory results have been published (11, 12 ) .
No studies to date have been able to identify SNPs in CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) that could account for the interindividual variation in CYP3A4 activity. A newly discovered SNP in intron 6 (rs35599367CϾT) may now explain this variability (6 ) . The purpose of our study was to test whether this new CYP3A4 SNP correlates with increased Tac exposure on standard dosages and thus might predict lower dose requirements.
Materials and Methods

PATIENTS AND STUDY DESIGN
Patients were de novo kidney transplant recipients participating in a phase IV, open, prospective, randomized controlled, international multicenter trial comparing fixed-dose (FD) with concentration-controlled (CC) mycophenolate mofetil treatment (FDCC study) (15 ) . Randomization to a fixed-dose or concentrationcontrolled regimen was done in blocks of 8 patients per center. Patients were randomized centrally through an automated telephone system, in a 1:1 ratio. A pharmacogenetic substudy was started in parallel. Findings on the roles of genetic polymorphisms in the UGT1A9 (UDP glucuronosyltransferase 1 family, polypeptide A9) gene for mycophenolate mofetil (16 ) , the UGT2B7 (UDP glucuronosyltransferase 2 family, polypeptide B7) gene for acyl-glucuronide mycophenolic acid (17 ) , and CYP3A5/ABCB1 for Tac exposure and acute rejection (18 ) in the FDCC study have previously been published. Patients provided separate written informed consent for the substudy. The protocol was approved by the ethics committees of all participating centers and the relevant authorities in participating countries.
Immunosuppressive therapy consisted of calcineurin inhibitor and corticosteroids. The choice of Tac or cyclosporine and the target blood concentrations for each drug were in accordance with each center's protocol. Oral Tac treatment began within 48 h before transplantation. Therapeutic drug monitoring was performed routinely, and centers were free to aim for the target concentrations they considered appropriate. A retrospective analysis showed that all centers started Tac with an aim of whole-blood concentrations of 7-15 g/L, tapering to 5-12 g/L at month 3 and to 4 -10 g/L at month 12. Corticosteroid tapering was recommended but not mandatory, and tapering regimens were left to the discretion of the investigators. In general, centers used higher doses in the first 2 weeks (20 -25 mg of prednisolone equivalent daily), lower doses thereafter (15 mg on week 4, 5 mg at month 3), and low-dose or no prednisolone during months 6 -12. More details can be found in the original FDCC study publication (15 ) . Genetic data were available for 185 kidney transplant recipients treated with Tac. Pharmacokinetic data were not always available for all patients at all time points. The C 0 was measured on days 3 and 10, at months 1, 3, 6, and 12 after transplantation, and whenever deemed necessary by the attending physician. Donor DNA was not collected, and no kidney biopsies were performed. Delayed graft function (DGF) was defined as a need for dialysis within the first week after transplantation. Biopsy-proven acute rejection (BPAR) was defined as any histologically confirmed episode with a Banff score Ն1. All biopsy samples were assessed locally by a pathologist.
DRUG CONCENTRATION MEASUREMENT
The C 0 was measured in whole blood in laboratories in each participating center by either the Tac II microparticulate enzyme immunoassay (Abbott Laboratories) or the enzyme-multiplied immunoassay technique (EMIT 2000; Syva Company/Dade Behring). The specificities of the 2 assays are comparable, and high correlations exist between the immunoassay and HPLC results (19, 20 ) . Although immunoassays overestimate Tac concentrations by up to 20% because of concurrent measurement of metabolites, this methodology has proved feasible for assessing differences in Tac concentrations with respect to the CYP3A5 genotype (21 ) . A limited number of centers used liquid chromatography-tandem mass spectrometry to measure Tac concentrations; this method was used for 30 (16%) of the 185 patients. Proficiency testing was performed by participation of all centers in the UK Quality Assessment Scheme. Dose-adjusted predose concentrations were calculated by dividing the C 0 by the corresponding 24-h dose on a milligram-per-kilogram basis.
GENOTYPE ANALYSIS
The MagnaPure LC System (Roche Diagnostics) was used to isolate genomic DNA from 200 L EDTAtreated whole blood. The CYP3A4 intron 6 CϾT genotype was determined with 50 ng genomic DNA in the allelic discrimination reaction performed with TaqMan (Applied Biosystems) genotyping assays (C_59013445 10) on an ABI PRISM 7500 ® Fast RealTime PCR System (Applied Biosystems). CYP3A5*3 analysis and ABCB1 1236CϾT, 2677GϾT/A, and 3435CϾT analyses were performed as described previously (18, 22 ) .
STATISTICAL ANALYSIS
Statistical analyses were performed with Predictive Analytics Software (PASW) statistics (version 17.0 for Windows; SPSS/IBM). C 0 and dose-adjusted C 0 values were normalized by logarithmic transformation. Kolmogorov-Smirnov tests confirmed that logtransformed data were normally distributed. For comparisons of 2 genotype groups, Student independent t-tests were used to compare the means at single time points. With Ͼ2 groups, ANOVAs were performed under the null hypothesis that the means of the compared groups were equal. When the differences between means were significant, we carried out a post hoc analysis consisting of an a priori polynomial linear contrast test to assess any potential linear trend according to genotype classification. The corresponding linear contrast does test the probability of a positive linear trend of the dependent variable across the ordered level of genotype classifications. Differences between groups were assumed statistically significant for P values Ͻ0.05. For univariate analyses of associations between categorical data (e.g., incidence of acute rejection), we used the Fisher exact test or the Pearson 2 test. The Tac daily dose and the dose-adjusted C 0 of different genotypes were compared with a mixed-model analysis, which was based on the maximum likelihood ratio, with patient genotype status as the fixed factor and time after transplantation as the repeated measurement. The sex, ethnicity, and age of the patients were introduced as random effects to adjust for these covariables. No structure was imposed on the variances and covariances between and within the times of follow-up of the repeated Tac measurements. We assumed levels of covariables (sex, ethnicity, and age) to be uncorrelated and to have a constant variance across the time of follow-up. Coefficients estimated from mixed-model ANOVA were back-transformed by taking their antilogarithm so that the data could become interpretable as percentage differences in geometric mean values of untransformed outcomes. Multiple logistic regression analysis was performed according to criteria defined by McMaster et al. (23 ) , with a fixed Tac supratherapeutic threshold set at 15 g/L. We computed genotypespecific odds ratios and 95% CIs by using backward stepwise analysis based on maximum likelihood ratios to assess the impact of genotype on the risk of Tac plasma concentrations Ͼ15 g/L. P values Ͻ0.05 were considered statistically significant for entry, and P values Ͻ0.10 were required for staying in the model. For these analyses, each genotype was coded as a "dummy variable." Table 1 summarizes the patient characteristics. Overall, 173 patients were homozygous for the CYP3A4 intron 6 wild type (rs35599367CC), 11 patients were heterozygous (rs35599367CT), and 1 patient was homozygous for the T variant (rs35599367TT), resulting in a minor-allele (T) frequency of 3.5%. The observed genotype distribution was in accordance with the Hardy-Weinberg equilibrium (P ϭ 0.25, 2 test). Heterozygous CT and homozygous TT variants were grouped and analyzed together as carriers of the rs35599367 T allele, against the patients homozygous for the wild type (rs35599367CC). We observed no linkage disequilibrium between the CYP3A4 intron 6 SNP and either the CYP3A5*3 or CYP3A4*1B allele [ 2 (2) ϭ 0.24 (P ϭ 1.0) and 1.36 (P ϭ 0.46), respectively].
Results
CYP3A4 INTRON 6 GENOTYPE AND Tac EXPOSURE
The 2 CYP3A4 intron 6 genotype groups were comparable with respect to the Tac daily dose on day 3 after transplantation: 13.3 mg/day for the wild-type CC patients vs 13.0 mg/day for the carriers of 1 or 2 T alleles (P ϭ 0.84, Table 2 ; see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol57/issue11). With these comparable dosages, the C 0 was higher for carriers of the T variant than for CC patients: 20.5 g/L vs 14.9 g/L (P ϭ 0.05, Table 2 ; see Fig. 1 in the online Data Supplement). The differences between the 2 groups in C 0 were not observed at later time points (P Ͼ 0.05, Table 2 ; see Fig. 1 in the online Data Supplement), but carriers of the T allele required significantly lower Tac doses than CC patients to reach this C 0 , from day 10 to month 6 (Table 2; see Fig. 1 in the online Data Supplement). Identical trends were observed when dose was adjusted for weight ( Table 2) . Analysis of repeated measurement in a mixed model demonstrated overall mean daily Tac dose requirements (adjusted for covariates age, sex, and ethnicity) to be 33% lower for carriers of the T allele (95% CI, Ϫ46% to Ϫ20%; P ϭ 0.018) than for CC patients. Consequently, the calculated dose-adjusted C 0 was lower for CC patients than for CT/TT patients. These differences were significantly different at day 10 and month 1 after transplantation (Table 2 ; see Fig. 1 in the online Data Supplement), but not at later time points, a result that might be explained by a decrease in the number of participants, thereby yielding a larger 95% CI. The mixed model for repeated measurements showed that the overall mean dose-adjusted C 0 (adjusted for the covariates of age, sex, and ethnicity) was 47% higher in carriers of the T variant (95% CI, 8%-100%; P ϭ 0.001) than the wild-type CC patients. As stated earlier, immunoassays overestimate Tac concentrations in blood by up to 20%, which may have influenced our results; however, the proportions of T variant carriers in the immunoassay group and the HPLC group were the same (6.5% and 6.7%, respectively; P ϭ 1.0, Fisher exact test). Moreover, when the analytical method for measuring Tac concentration was introduced as a random effect, carriers of the T allele still showed a higher overall dose-adjusted C 0 (ϩ37% for T allele carriers, P Ͻ 0.001) and a lower Tac daily dose (Ϫ20% for T allele carriers, P ϭ 0.007) than the wild-type CC patients. For the ABCB1 gene, neither 2677GϾT/A nor 1236CϾT was associated with differences in Tac pharmacokinetics during the entire study. Also ABCB1 3435CϾT was not significantly associated with Tac dose and dose-adjusted Tac exposure in a linear mixed model when the CYP3A4 genotype was not taken into account as previously reported (18 ) . When ABCB1 haplotypes were generated, no differences between the ABCB1 CGC (n ϭ 26) and TTT haplotype groups (n ϭ 20) were observed with respect to Tac dose and doseadjusted Tac exposure (data not shown).
COMBINED EFFECTS OF CYP3A4 INTRON 6 GENOTYPE, CYP3A5*3,
AND ABCB1 3435C>T
We investigated the effects of CYP3A4 intron 6, ABCB1 3435CϾT, and CYP3A5*3 genotypes in combination. Patients carrying 1 or 2 CYP3A5*1 alleles (CYP3A5 expressers) were compared with CYP3A5*3/*3 nonexpressers. In the mixed-model analysis adjusted for the covariates of age, sex, and ethnicity and including ABCB1 3435CϾT, CYP3A5*3, and CYP3A4 intron 6 genotype status as fixed effects, all investigated SNPs were significantly correlated with dose-adjusted Tac exposure. Overall, the dose-adjusted C 0 was 43% higher among patients with CYP3A4 intron 6 CT/TT (95% CI, 13%-88%; P Ͻ 0.001) than among CC patients and was 43.3% lower among CYP3A5 expressers than among nonexpressers (95% CI, Ϫ52.7% to Ϫ32.1%; P ϭ 0.001). Regarding ABCB1 3435TT individuals, patients with ABCB1 3435CT and 3435CC genotypes had a lower overall dose-adjusted C 0 : Ϫ14.3% (95% CI, Ϫ26.2% to Ϫ0.5%; P ϭ 0.042) and Ϫ20.9% (95% CI, Ϫ32.7% to Ϫ7.1%; P ϭ 0.003), respectively. Only CYP3A4 intron 6 and CYP3A5 genotypes correlated significantly with the Tac dose requirement, because ABCB1 3435CϾT genotype status was no longer a significant fixed effect in the mixed model. In this final model, the Tac dose requirement was 25% lower for carriers of the T allele (95% CI, Ϫ43% to Ϫ7%; P ϭ 0.04) than for CC patients and was 63.7% higher for patients who expressed CYP3A5 than for nonexpressers (95% CI, 39.1%-88.2%; P Ͻ 0.001).
Because the effects of the CYP3A4 intron 6 and CYP3A5*3 SNPs appeared independent, we combined genotype groups. Group 1 contained CYP3A5 nonexpressers and carriers of the CYP3A4 intron 6 T variant (poor metabolizers); group 2 contained CYP3A5 nonexpressers and CYP3A4 intron 6 CC patients (intermediate-1 metabolizers); group 3 clustered CYP3A5 expressers carrying the CYP3A4 intron 6 T allele (intermediate-2 metabolizers); and group 4 merged CYP3A5 expressers with individuals with the CYP3A4 intron 6 CC wild type (extensive metabolizers) ( Table 3 ). The C 0 values of the groups were significantly different at the first visits ( Table 4 ). The Tac daily-dose requirements, which were based on reaching the target C 0 by therapeutic drug monitoring, were significantly different from day 10 and remained so (Table 4) . Identical significant differences were observed when dose was adjusted for patient weight (Table 4). The dose-adjusted C 0 was significantly different among groups at all time points (Table 4 ; see Fig. 1 in the online Data Supplement). This trend was linear and was a function of genotype category classification, either for the C 0 at day 3 (group 1 Ͼ group 2 Ͼ group 3 Ͼ group 4; P Ͻ 0.004; Table 4 ) or for the Tac dose requirement from day 10 to month 12 (group 1 Ͻ group 2 Ͻ group 3 Ͻ group 4; P ϭ 0.001; Table 4 ). This trend was also observed for the dose-adjusted C 0 and was highly significant at all investigated time points (group 1 Ͼ group 2 Ͼ group 3 Ͼ group 4; P ϭ 0.006; Table 4 ). The mixed-model analysis revealed an overall increase in the Tac dose-adjusted trough blood concentration of ϩ179.3% for the poor metabolizer cluster (P Ͻ 0.001), ϩ101.4% for the intermediate-1 metabolizer cluster (P Ͻ 0.001), and ϩ64.4% for the intermediate-2 metabolizer cluster (P ϭ 0.020), compared with the extensive metabolizers.
Patients from groups 1 and 2 had a day 3 C 0 geometric mean above the consensus supratherapeutic threshold (15 g/L): 21.5 g/L for group 1 and 15.8 g/L for group 2. Logistic regression models showed that the risk of presenting a supratherapeutic C 0 at day 3 was significantly higher for group 1 (odds ratio, 8.3; 95% CI, 1.3-57.0; P ϭ 0.027) and group 2 (odds ratio, 4.7; 95% CI, 1.9 -13.4; P ϭ 0.002), compared with group 4 (Fig. 1) . Group 3 was excluded from the analysis because C 0 data were available for only a single patient (C 0 ϭ 14.9 g/L). No significant differences were observed across the different genotype clusters with respect to the risk of a C 0 Ͻ10 g/L (data not shown).
CYP3A4 GENOTYPE, DGF, CREATININE CLEARANCE, AND ACUTE
REJECTION
Of the 185 patients, DGF was observed in 38 patients, 2 of whom carried the CYP3A4 intron 6 T allele. No significant differences were observed in DGF incidence [ 2 (1) ϭ 0.12; P ϭ 0.72] or in creatinine clearance (Table 2) between T variant carriers and CC patients. Similarly, we observed no differences between groups of combined genotypes for CYP3A4 and CYP3A5 SNPs, in creatinine clearance (Table 4) . BPAR occurred in 37 of the 185 patients, 4 of whom carried CYP3A4 intron 6 variant T, but no significant differences in BPAR incidence were observed between carriers of the T variant and CC patients [ 2 (1) ϭ 1.42; P ϭ 0.23]. Similarly, we did not find any significant difference in the incidence of either DGF or BPAR among different clusters of combined genotypes with respect to CYP3A4 intron 6 and CYP3A5*3 allelic status [ 2 (3) ϭ 0.66 (P ϭ 0.89) and 4.52 (P ϭ 0.18), respectively].
Discussion
We show for the first time that the new CYP3A4 intron 6 CϾT SNP is associated with lower Tac dose requirements, in agreement with the reduced function of this Table 4 . Tac dose, C 0 , and dose-adjusted C 0 according to the combined CYP3A4 intron 6 C>T SNP and CYP3A5 genotype. CYP3A4 variant and the expected reduced clearance of Tac (6 ) . We have demonstrated that de novo kidney transplant recipients who carry 1 or 2 T alleles require significantly lower Tac doses to reach the target C 0 than wild-type CC patients. During the first year after transplantation, carriers of the T allele required a 33% lower mean Tac dose compared with the wild-type patients. Our findings are in agreement with those of Wang et al., who addressed the functional defect caused by this SNP (6 ) and showed that this SNP is significantly linked to reductions in CYP3A4 mRNA production and enzyme activity in human livers. Thus far, this CYP3A4 SNP is the only one that has a relatively high allele frequency in Caucasians (2.5%-6.9%, http:// www.ncbi.nlm.nih.gov/projects/SNP) and that shows such a large effect. A recent report by Jacobson et al. (24 ) described 3 other CYP3A4 polymorphisms with respect to Tac pharmacokinetics, but these were observed only in Africans. In our study, only 8 of the patients were of African origin, which is why we did not include these SNPs.
Combining CYP3A4 and CYP3A5 genotypes revealed an increased significance of the observed effects on Tac pharmacokinetics compared with the CYP3A4 or CYP3A5 genotype alone. This effect was allele-dose dependent and was influenced quantitatively by genotype classification: at all time points, the Tac dose requirement was lowest for CYP3A poor metabolizers, followed by intermediate-1 metabolizers, intermediate-2 metabolizers, and, finally, extensive metabolizers. All groups were significantly different (P ϭ 0.001), except for day 3 (P ϭ 0.78). This latter observation reflects the fact that at this time point no dose adjustments could have been made on the basis of therapeutic drug monitoring, and dosing thus was independent of genotype or metabolizer status. Similarly, the dose-adjusted C 0 was affected significantly by the CYP3A4 and CYP3A5 combined genotype: extensive metabolizers Ͻ intermediate-2 metabolizers Ͻ intermediate-1 metabolizers Ͻ poor metabolizers-demonstrating that poor metabolizers require lower doses to achieve a target C 0 at all time points (including at day 3 after transplantation) than the other groups. Therefore, genotype classification might lead to a better prediction of the optimal Tac starting dose.
The risk of a supratherapeutic C 0 (Ͼ15 g/L) on day 3 was significantly higher for poor and intermediate-1 metabolizers than for extensive metabolizers. This risk was even more pronounced among poor metabolizers than among intermediate-1 metabolizers. We observed that both poor and intermediate-1 metabolizers had a mean C 0 at day 3 of Ͼ15 g/L (21.5 g/L and 15.8 g/L, respectively). We reported earlier that a significantly larger proportion of patients carrying the CYP3A5*1 allele had a C 0 Ͻ10 g/L (18 ) . When the genetic status for the CYP3A4 intron 6 SNP was taken into account, no significant differences were observed with respect to the risk of presenting a Tac concentration below this threshold (data not shown). As was recently suggested, it is likely that clinicians are able to target the C 0 above this threshold rapidly after transplantation by performing New CYP3A4 SNP Affects Tacrolimus Metabolism simple concentration-controlled Tac dose adjustments without consideration of CYP3A5 status (13 ) . In the present study, 15% of patients had a C 0 Ͻ10 g/L at day 3, and 2 patients had a C 0 Ͻ5 g/L. Approximately 50% of the patients had a C 0 Ͼ15 g/L. Neither a subtherapeutic C 0 at day 3 nor the CYP3A5*1 allele was associated with BPAR within 1 month after surgery (data not shown), a result in accordance with previous studies (18, 21, (25) (26) (27) . We found that 50% of patients did overshoot the upper limit of Tac exposure, whereas only 15% had Tac exposures of Ͻ10 g/L. This result indicates that overexposure is a problem more frequently encountered than underexposure. It may be especially relevant in patients experiencing DGF. Regarding ABCB1, we found the 3435CϾT SNP to be independently associated with the dose-adjusted C 0 . The influence of this SNP (14.3% and 20.9% lower dose-adjusted C 0 for heterozygotes and homozygotes, respectively) was modest compared with the effects of the CYP3A4 and CYP3A5 polymorphisms and disappeared in the mixed-model analysis in which the CYP3A4 and CYP3A5 genotype were included. The relatively minor contribution of the ABCB1 polymorphism to Tac pharmacokinetics is in line with previous investigations (28 -30 ) .
The present study has limitations. Although most participating centers have used immunoassays to measure Tac concentrations, some centers applied a liquid chromatography-tandem mass spectrometry approach. In an additional mixed-model analysis in which we adjusted for Tac assay by introducing a dummy variable as a random effect, the effect of CYP3A4 intron 6 genotype was still significant, both for the Tac daily dose (Ϫ20% for carriers of the T allele, P ϭ 0.007) and for the dose-adjusted C 0 (ϩ37% for T allele carriers, P Ͻ 0.001). Second, corticosteroids are known to influence Tac exposure (31, 32 ) . Given that corticosteroid tapering was recommended but not mandatory, the different centers may have used different corticosteroid regimens, which we cannot exclude from having influenced the analysis. If all patients had been treated with the same dose, the influence of genotype might have been stronger by reducing the uncontrolled variation generated by different tapering regimens. Unfortunately, the corticosteroid dose could not be included in the mixed-model analysis because different formulations with different immunosuppressive potencies were used. Third, diabetic gastrointestinalmotility disorders can affect Tac pharmacokinetics. Although diabetic gastropathy may alter the curve of the Tac area under the ROC curve during a dosing interval, C 0 values are generally less affected (33 ), and we therefore believe that the influence of diabetes on the outcomes of the present study was limited. Fourth, our set contained some missing data points. To overcome this limitation, we performed mixed-model analysis, which compensates for missing records. The correct use of mixed-model analysis requires that data be missing at random. We investigated this criterion, and, indeed, the proportion of missing data for carriers of the CYP3A4 intron 6 T allele was not significantly different from that of noncarriers with respect to C 0 (P ϭ 0.71), Tac dose (P ϭ 0.14), C 0 /dose (P ϭ 0.28), and creatinine clearance (P ϭ 0.24). Finally, we realize that our findings are significant at a 95% CI. Therefore, our results need to be confirmed with independent cohorts.
In conclusion, we have shown that the new genetic CYP3A4 intron 6 polymorphism was associated with reduced Tac clearance in our patient cohort. Therefore, pretransplantation genotyping of the CYP3A4 intron 6 CϾT SNP, along with CYP3A5*3, could potentially benefit patients by reducing initial Tac doses among CYP3A poor metabolizers and thereby reduce the risk of reaching supratherapeutic Tac concentrations.
